Selective norepinephrine reuptake inhibitor
Selective noradrenaline reuptake inhibitors ( NARI = noradrenaline reuptake inhibitor or NERI = norEpinephrine RI ) are an active class of antidepressants . These psychotropic drugs develop their effect selectively on the noradrenaline transporter in the brain.
pharmacology
Selective noradrenaline reuptake inhibitor (NARI) binding in the central nervous system at the norepinephrine - transporter and thereby inhibit the reuptake ( Re-uptake ) of this neurotransmitter in the presynaptic terminal . In this way, at least initially, they increase its concentration in the synaptic cleft.
As with all antidepressants, the antidepressant effect is probably due to the higher availability of neurotransmitters due to the adaptation of the receptors and similar structures, which occurs with a latency period. Dopamine and serotonin transporters are almost not occupied by the NARI, hence the term selective . NARI have fewer side effects than the older tricyclic antidepressants . The latter also interact with other neuroreceptors and therefore act e.g. B. antihistaminic or anticholinergic .
Active pharmaceutical ingredients
Although never approved, nisoxetine is used as a reference substance in research.
In Germany, the following substances were or are approved for the following areas of application:
As an antidepressant:
- Reboxetine ( Solvex ® , Edronax ® )
- Viloxazin ( Vivalan ® ; approval was no longer extended by the manufacturer, so the agent is no longer available)
To treat attention deficit / hyperactivity disorder (ADHD ):
- Atomoxetine ( Strattera ® )
Approved for the treatment of obesity:
As a skeletal muscle relaxant:
- Orphenadrine ( Norflex ® )
Side effects
- Dry mouth
- Urinary retention
- nausea
- Sexual dysfunction
- Loss of appetite
- Restlessness
- sleep disorders
- Feeling cold
